Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-08-14

Intellia Therapeutics, Inc.

Intellia develops in vivo CRISPR gene-editing therapies for hereditary angioedema, transthyretin amyloidosis and other severe diseases.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From CRISPR promise to first franchise

The key question is whether a positive HAE program becomes a real commercial business rather than another admired dataset. If that conversion works and ATTR remains alive, the stock can compound well above market norms without requiring a heroic platform narrative.

Analysis

Thesis

If lonvo-z clears filing, approval and payer onboarding, Intellia can convert from a collaboration-funded CRISPR platform into a focused rare-disease franchise with meaningful HAE revenue by 2031, while nex-z and structured licensing add option value without needing a full blue-sky platform rerating.

Last Economy Alignment

AI helps Intellia compress discovery, CMC and clinical execution, but value capture still rests on regulated therapies, IP and treatment-pathway control rather than software-like scale.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

4.4x (from 5 most recent analyses)

Reasoning

The realistic upside is not a 10x meme rerating; it is a company-shape change. A successful HAE launch would move revenue quality from lumpy collaboration income toward durable product revenue, and even partial validation of nex-z would make the platform feel repeatable rather than singular. That combination can support a materially larger enterprise, but the stock still needs proof in approval, reimbursement and launch execution before it deserves a premium rare-disease multiple.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The core risk is conversion risk: Intellia must turn strong lonvo-z data into a filed and accepted BLA, a workable label, payer access and real treatment-center throughput. If nex-z does not regain credible second-asset status, the company may earn approval without earning the broader platform rerating that makes the 2031 upside compelling.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

August 6 results reiterated expected FDA BLA acceptance for lonvo-z in second half of 2026 and planned U.S. launch in first half of 2027.
Second-quarter cash of 628 and guidance to fund operations into 2028 reduced near-term financing pressure versus earlier in the year.
Management said field medical, reimbursement and strategic accounts teams are finalized, making the story more about launch conversion than abstract science.
No new negative regulatory surprise emerged in the last 7-10 days; the near-term stock remains primarily tied to filing acceptance and MAGNITUDE-2 enrollment timing.

Forecast update

Confidence improved modestly because balance-sheet visibility and launch-readiness evidence are better than in the prior run, though the second-asset proof burden still caps rerating.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.35

They control regulated gene-editing know-how and are building the treatment-center and payer workflow needed to get one-time therapies approved, delivered and paid for. AI can help them move faster, but FDA decisions, safety and rival modalities still matter more than software-style scale.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.85

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research